Regorafenib is a chemotherapy drug prescribed to treat metastatic colorectal cancer, a type of cancer that starts in the colon or rectum and has spread to other areas of the body. This drug works by interrupting the process the cancer cells need to grow and divide, which can help slow down the progression of the disease. Regorafenib is approved for use in adults only.
An Overview of Uses for Regorafenib
Regorafenib (Stivarga®) is a prescription anticancer medication approved for the treatment of colorectal cancer that has spread to other parts of the body (metastasized). It is used in people who have previously been treated with certain other chemotherapy medicines.
Regorafenib Use for Colorectal Cancer
Colorectal cancer is cancer that starts in the tissue of the colon (the large intestine) or the rectum (the lower part of the colon). Cancer that begins in the colon is called colon cancer, while cancer that begins in the rectum is called rectal cancer. Colorectal cancer is another name for these forms of cancer.
Most colorectal cancer begins as small growths on the inside of the large intestine called colon polyps. The majority of colon polyps are noncancerous but, over time, some types of polyps become cancerous. Because most people with colon polyps experience no symptoms, healthcare providers recommend screening for certain individuals to find and remove polyps before they become cancerous, or to detect early colorectal cancer (see Colorectal Cancer Screening for more information).
Once colorectal cancer is diagnosed, there are a variety of treatment options. The type of treatment recommended depends largely on the location of the tumor in the colon or rectum and the stage of the cancer. The stage of cancer describes whether the cancer has spread and, if so, to what parts of the body. In general, treatment may include surgery, radiation, or anticancer medications.
Regorafenib is a type of anticancer treatment that may help slow down or stop the growth of cancer cells, thereby slowing down the progression of colorectal cancer. It is used in metastatic colorectal cancer, which means the cancer has spread beyond the colon and rectum to other parts of the body. As mentioned previously, regorafenib is used in people whose cancer progressed after treatment with certain other chemotherapy medicines.
Food and Drug Administration (FDA) news release. FDA approves new treatment for advanced colorectal cancer. September 27, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321271.htm. Accessed October 9, 2012.
Micromedex 2.0 Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare), Inc. Updated periodically. Accessed October 9, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click